The FDA approval of vepdegestrant for ESR1-mutant ER+/HER2− advanced breast cancer marks an important milestone for PROTACs!
Beyond its importance for patients, this is a landmark validation of targeted protein degradation as a therapeutic modality 👏🏻
www.fda.gov/drugs/resour...
fda.gov
FDA approves vepdegestrant for ER-positive, HER2-negative, ESR1-mutate
FDA approves vepdegestrant for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer